Objective: b-Blockers improve outcomes in patients with heart failure or a history of myocardial infarction, but it remains uncertain whether they are beneficial after the perioperative period in cardiac surgery patients without these conditions. This study was designed to examine whether discharge use of b-blockers was associated with outcomes after hospitalization in patients who had undergone nontransplant cardiac surgery.
Methods:
We analyzed outcomes in a prospective cohort of 3102 patients discharged alive after cardiac surgery (2547 of whom had undergone coronary artery bypass grafting surgery) between September 2002 and August 2005.
Results: b-Blockers were prescribed for 2580 (83%) patients at hospital discharge. Over a mean follow-up of 75 months (standard deviation, 20 months), 10% (259/2580) of patients discharged with b-blockers and 19% (97/522) not prescribed b-blockers at the time of hospital discharge died (hazard ratio of 0.65 [95% confidence interval, 0.49-0.87] after adjustment for covariates). One-year mortality was also lower in those discharged with b-blockers: 2.2% (57/2580) in b-blocker users versus 7.2% (38/522) in nonusers (adjusted odds ratio, 0.54 [95% confidence interval, 0.30-0.97]). The association between b-blocker use and lower mortality was consistent across all examined subgroups, including patients without prior myocardial infarction or without heart failure (all P < .01).
Conclusions: Patients discharged with b-blockers after cardiac surgery exhibit a substantially lower mortality rate during long-term follow-up, even among those without a history of myocardial infarction or heart failure. (J Thorac Cardiovasc Surg 2010;140:182-7)
Supplemental material is available online.
It is well established that b-blockers improve outcomes in patients after acute myocardial infarction (MI), 1 as well as in patients with heart failure. 2 Although there is little ran-domized trial evidence, 3 preoperative use of b-blockers is associated with reduced rates of perioperative cardiovascular events after coronary artery bypass grafting (CABG) surgery in observational studies. [4] [5] [6] However, these studies have largely examined outcomes in the first few days after surgical intervention, and whether b-blockers should be continued at the time of discharge after cardiac surgery remains a topic of debate.
Although some opinion leaders recommend the use of b-blockers in all patients after CABG, 7 the only randomized trial that evaluated b-blockers after CABG did not find any clinical benefits with metoprolol compared with placebo. 8 Likewise, a secondary analysis of data from the Project of Ex-vivo Vein graft Engineering via Transfection IV (PRE-VENT IV) trial failed to demonstrate any significant association between b-blocker use at the time of discharge and the rate of death or MI in the 2 years after CABG. 9 However, these negative results were based on small numbers (81 cardiac events in the MACB trial and 147 deaths or MI in PRE-VENT IV). Although analyses from the Cooperative Cardiovascular Project did report significantly lower mortality 10 in post-CABG patients who were taking b-blockers at the time of discharge, it is important to note that all of these patients underwent CABG after an acute MI. Similarly, although an analysis of elderly Medicare patients reported a lower mortality rate (hazard ratio, 0.88; 95% confidence interval [CI], 0.81-0.97) in the subsequent 4 years in those who were discharged with b-blockers, these patients were elderly (average age, 76 years), and more than half had heart failure. 11 Thus these 2 studies could not answer the question of whether b-blockers should be administered to all patients after CABG or merely to those with history of recent MI or heart failure. Although the American College of Cardiology/ American Heart Association guidelines recommend longterm aspirin and statin therapy in all patients after CABG, their comments on b-blocker use are limited to encouraging their use in the immediate perioperative period to reduce the risk of atrial fibrillation. 12 Thus we designed this study to investigate the effect of b-blocker use after the immediate perioperative period in patients undergoing nontransplant cardiac surgery on all-cause mortality using data from the Alberta Provincial Project for Outcome Assessment in Coronary Heart Disease (APPROACH). 13 
MATERIALS AND METHODS Study Cohort
All adult patients undergoing nontransplant cardiac surgery at the University of Alberta Hospital in Edmonton, Alberta, Canada, were prospectively enrolled into APPROACH 13 during the study period between September 2002 and August 2005 (n ¼ 3864). The APPROACH study has been approved by the University of Alberta Health Research Ethics Board, and all study participants provided written informed consent before study entry. We excluded patients who died during the index surgical hospitalization (n ¼ 13) or for whom we did not have data on discharge medications (n ¼ 749). As a result, our cohort consisted of 3102 patients who underwent nontransplant cardiac surgery, who survived to discharge, and for whom we had discharge medication data. Of note, baseline demographics and comorbidities were similar in those patients with or without data on discharge medications.
Data Collection and Variables
Baseline information on demographic and clinical factors were collected through the APPROACH Project (in which all diagnoses before index cardiac catheterization are assigned by cardiologists and all data are double checked and entered into the database by specially trained cardiac nurses). Laboratory and medication data were collected at the time of preoperative CABG assessment, as described previously. 14 Discharge medication data were collected from review of discharge summaries.
Exposure
The exposure variable of interest was the use of b-blockers at the time of discharge after cardiac surgery.
Outcome
Vital status for all APPROACH patients is obtained through linkage to the registry file of Alberta Health and Wellness, and we obtained mortality data up to October 31, 2008. In addition, 30-day mortality rates for all patients undergoing cardiac surgery are collected by specially trained cardiac nurses from review of medical records.
Statistical Analyses
We compared demographics, clinical characteristics, and medication use in those patients who were discharged with b-blockers (vs not) by using the c 2 test for dichotomous variables and Student's t test for continuous variables. We examined the association between b-blocker prescription at discharge and mortality. Our primary analysis was for 1-year mortality, but in sensitivity analyses we examined mortality in the first 30 days after discharge, mortality 31 to 365 days after hospital discharge, and long-term mortality. In addition, we conducted subgroup analyses in which we examined the association between b-blocker use and outcomes in various subgroups defined by baseline characteristics.
In those patients who underwent CABG, we used multiple logistic regression to adjust for those variables that were associated with mortality after hospital discharge to test whether the associations between discharge prescription for b-blockers and mortality were robust. We considered for inclusion in our multivariate models any factors in Table 1 that were imbalanced between arms (at a P < .2), had a prevalence of at least 1%, and were associated (on bivariate analysis) with 1-year mortality after hospital discharge or were believed to be important to include based on prior literature, clinical experience (including year of operation), or both. We selected the variables for our models using the backward stepwise selection technique with an entry P value of .25 or less and an exit P value of .05 (see Table 2 for the results of these multivariate analyses). We examined all first-order interaction terms, but none achieved a level of significance of a P value of less than .10. We also conducted a Cox proportional hazards analysis to examine whether b-blocker use at hospital discharge was associated with long-term mortality in patients discharged from the hospital after adjusting for those covariates that were associated with long-term mortality in our cohort, as well as other discharge medications. Finally, as a sensitivity analysis, we performed a conditional logistic regression analysis on a propensity-matched subset of patients undergoing CABG matched on their predicted probability of receiving a b-blocker (by using the greedy matching technique after developing predicted probabilities [ie, propensity scores] for receiving a b-blocker for every patient in the cohort based on baseline characteristics, including age, sex, comorbidities, and other medications). 15 All analyses were conducted with SPSS version 17.0 software (SPSS, Inc, Chicago, Ill), except for the analysis of long-term mortality, for which SAS version 9.0 software (SAS Institute, Inc, Cary, NC) was used.
RESULTS
Of the 3102 patients in our cohort, 2547 (82%) underwent CABG (99% on pump). At discharge, 2580 (83%) patients were prescribed a b-blocker. The imbalances in prognostic factors generally favored the b-blocker nonusers because they had a lower burden of comorbidities and were less likely to be undergoing urgent/emergency CABG (Table  1 ). In those patients who had their left ventricular ejection fraction measured, reduced systolic function was more common in b-blocker users than nonusers (Table 1) . Those patients discharged with b-blockers were more likely to be male and were more likely to be discharged with aspirin or other antiplatelet agents, angiotensin-converting enzyme (ACE) inhibitors, or statins (all highly statistically significant, Table 1 ). Although there was no difference in preoperative Duke Jeopardy score (which approximates the amount of myocardium at ischemic risk and is predictive of 1-year mortality in patients undergoing CABG 16 ) between those discharged with b-blockers and those not, those who were discharged with b-blockers appeared to have less complicated operations based on the differences in controlled cardiac ischemia time (74.3 vs 94.9 minutes, P < .001). Similar differences between b-blocker users and nonusers were observed when comparisons were restricted to the 2547 patients who underwent CABG (see Table E1 ). Over a mean follow-up of 75.2 months (standard deviation, 20.2 months), 10% (259/2580) of those who were discharged with b-blockers and 19% (97/522) of those who were not prescribed b-blockers at the time of hospital discharge died ( Figure 1 ). In the first year after surgical discharge, 2.2% (57/2580) of b-blocker users and 7.3% (38/522) of nonusers died (compared with 6% [44/736] of those patients for whom we did not have discharge prescription data). Even after excluding the 25 patients who died within the first 4 weeks of discharge after their cardiac surgery (9/2580 b-blocker users vs 16/522 nonusers; unadjusted odds ratio [OR], 0.11; 95% CI, 0.05-0.25), discharge b-blocker users were less likely to die in months 2 to 12 postoperatively (48/2571 b-blocker users vs 22/ 506 nonusers; unadjusted OR, 0.42, 95% CI, 0.25-0.70).
Subgroup analyses confirmed that the association between b-blocker use and lower mortality was consistent across all examined subgroups, including patients without a history of MI or heart failure ( Figure 2 ). Of note, although the associations between b-blocker use and mortality were nonsignificant for female patients and those who underwent non-CABG operations, this reflected the low number of patients in these subgroups rather than any qualitative difference between subgroups because all statistical tests for interaction were nonsignificant. Similar consistency of effect across subgroups was seen in the 2547 patients who underwent CABG operations ( Figure 3 ). Moreover, the association between b-blocker discharge and lower 1-year mortality was consistent across study years (from an OR of 0.32 [95% CI, 0.12-0.84] in those patients undergoing operations in 2002 to an OR of 0.24 [95% CI, 0.11-0.54] in those patients undergoing operations in 2005). Discharge b-blocker use was associated with substantially lower 1-year mortality rates in the 251 patients who were not discharged with aspirin (4.9% vs 45%; OR, 0.06; 95% CI, 0.03-0.14), the 927 patients who were not discharged with a statin (3.4% vs 15.4%; OR, 0.20; 95% CI, 0.12-0.33), and the 133 patients who were not discharged with aspirin or a statin (3.1% vs 55.6%; OR, 0.03; 95% CI, 0.01-0.11). Patients who were discharged with aspirin and a statin had lower 1-year mortality rates (1.7%), and although discharge b-blocker use was still associated with lower 1-year mortality in this subgroup (OR, 0.68), this did not achieve statistical significance (95% CI, 0.26-1.77) because of the small number of deaths in this subgroup.
Variables associated with 1-year postoperative mortality in patients undergoing CABG are outlined in Table 2 (c-statistic for this model ¼ 0.801). After adjusting for these covariates in multivariate analysis, discharge b-blocker use remained significantly associated with a lower risk of 1-year mortality (adjusted OR, 0.54; 95% CI, 0.30-0.97). Even after excluding the 20 patients undergoing CABG who died within the first 4 weeks of discharge, the association between discharge b-blocker use and lower mortality at 1 year persisted after covariate adjustment (adjusted OR, 0.56; 95% CI, 0.29-1.07), although it fell short of statistical significance because of the smaller number of deaths in this analysis. On Cox proportional hazards analysis adjusting for the covariates in Table 2 and examining survival over a mean follow-up of over 6 years, the hazard ratio for long-term mortality associated with b-blocker use at the time of hospital discharge was 0.65 (95% CI, 0.49-0.87). In our propensity-matched sensitivity analysis we were able to match 288 of the 303 b-blocker nonusers after CABG surgery with 288 b-blocker users with the same propensity for b-blocker prescription based on the identified covariates. The model run on this 576 patient subgroup demonstrated a similar association between b-blocker use and lower 1-year mortality (OR, 0.53) as our primary analysis, although it did not achieve statistical significance (P ¼ .16) because of the smaller sample size compared with the full cohort used in our primary analysis. Of the 2580 patients discharged with a b-blocker, 641 had not been taking a b-blocker preoperatively. Of the 522 patients discharged without a b-blocker prescription, 194 had been taking a b-blocker preoperatively. The mortality rates in the 194 patients who had their b-blockers stopped after the operation were 3.6% in the first 30 days after discharge, 9.8% at 1 year, and 22.7% over the mean follow-up of 50.4 months.
DISCUSSION
In summary, we found that those patients who were discharged with b-blockers after cardiac surgery exhibited a substantially lower rate of death at 1 year, which was consistent across subgroups and robust to multivariate adjustment. The association between discharge b-blocker use and lower mortality persisted even after excluding deaths within the first 4 weeks after discharge and even when extending follow-up to more than 6 years. Importantly, the lower mortality risk in b-blocker users was seen in all patients after cardiac surgery, including those without a prior history of MI or heart failure, and was particularly marked in patients after CABG and patients who were not discharged with aspirin, statins, or both.
Thus our findings extend the evidence base supporting the use of discharge b-blockers after cardiac surgery. Although earlier studies 10,11 demonstrated a similar association between discharge b-blocker use and lower mortality in patients undergoing CABG with a history of MI or heart failure, we have demonstrated a positive association between discharge b-blockers and survival that extends to all subgroups we considered. In addition, we have addressed criticisms that this association might simply reflect physician selection bias in only prescribing b-blockers to patients with good prognoses by demonstrating that the association between b-blocker use and lower mortality was preserved even after excluding those deaths that occurred in the first 4 weeks after discharge. Presumably, even if physicians are accurate in predicting which patients are most likely to do well, this prognostication ability is unlikely to extend more than a few weeks after hospital discharge. A potential mechanistic explanation for our findings arises from a pooled analysis of intravascular ultrasonographic trials that demonstrated that coronary atherosclerosis progression rates were significantly reduced in b-blocker users compared with those seen in patients not receiving b-blockade, even after multivariate adjustment. 17 Our study cohort is similar to other contemporary audits of cardiac surgery patients in demographics, clinical comor-bidities, and outcome rates. 18 Furthermore, our discharge prescribing rates for secondary prevention medications, although higher than those of studies of a decade ago, 10 are similar to more contemporaneous cohorts. 19, 20 We did not survey attending surgeons about why they chose to discharge some of their patients with b-blockers but not others. In addition to detecting a positive association between the use of b-blockers and lower mortality rates after cardiac surgery, our study also demonstrated that the use of aspirin and statins is strongly associated with lower postoperative mortality at 1 year. These findings support previous reports showing that early initiation of aspirin 21 or statins 22 after cardiac surgery reduces the risk of death. The Ischemia Management with Accupril post-bypass Graft via Inhibition of the converting Enzyme (IMAGINE) trial found that early initiation of ACE inhibitors after CABG in stable patients without heart failure, diabetes, or prior MI was associated with early excess angina but a subsequent trend toward reduced cardiovascular events and death that did not achieve statistical significance because of the low event rates in trial participants. 23 A recent cohort study also suggested that use of ACE inhibitors in the immediate perioperative setting in patients undergoing CABG might in fact be associated with worsening of outcomes compared with those seen in patients not taking ACE inhibitors. 24 Thus our finding of a nonsignificant association between ACE inhibitor use and 1-year mortality but reduced long-term mortality in users of ACE inhibitors is consistent with both of these studies and the data from long-term ACE inhibitor trials demonstrating long-term benefits.
Our study has a number of strengths stemming from the prospective collection of data, including medications, on all patients (not just the elderly) undergoing nontransplant cardiac surgery in one tertiary care institution with 100% follow-up through linkage to electronic mortality records (thereby minimizing recall or ascertainment bias). However, there are some limitations.
First, our study is observational in nature. Despite the adjustment for known confounders in multivariate analyses, we can only investigate associations and cannot infer causation. However, the consistency of the association between b-blocker use and outcomes in various subgroups and over various time periods is persuasive. Moreover, it is worth noting that many of the imbalances in Table 1 favor the b-blocker nonusers, and this in fact strengthens our conclusion because the b-blocker users exhibited lower mortality rates despite a higher burden of comorbidities at baseline and a greater proportion of urgent/emergency CABG.
Second, we only have information on medications prescribed at the time of discharge after cardiac surgery and do not have data on the number of prescriptions actually filled and subsequent persistence with these prescriptions. However, data from another Canadian cohort study 19 demonstrated that b-blocker use is relatively stable after CABG discharge, with only a 7% decrease (from 71% to 64%) after 1 year. Regardless, any nonadherence to b-blockers after discharge in our study cohort would have biased our study toward the null, making it more difficult to detect an association between discharge b-blocker use and 1-year mortality.
Third, we do not have data on the dosage of medications used and thus could not explore for dose-response effects.
Fourth, we do not have data on MI or ischemia at the time of the operation or after hospital discharge, and future studies should investigate the incidence of such events after cardiac surgery because presumably the benefits of b-blockade might well be through their anti-ischemic mechanisms, antiarrhythmic mechanisms, or both.
Finally, we do not have data on such operative factors as number and type of bypass grafts, surgical techniques, and myocardial protection techniques nor any details on the severity of comorbidities in this patient population (although our findings were maintained even after adjusting for key objective measures, such as left ventricular ejection fraction and Duke Jeopardy score).
In conclusion, despite advances in intraoperative techniques and perioperative care that have resulted in improved short-term outcomes, long-term outcomes after cardiac surgery have not demonstrated the same impressive improvements over the past 2 decades. 25 It has been speculated that this might be due to suboptimal use of secondary prevention therapies after discharge from surgical intervention. Certainly, patients after cardiac surgery appear to be less likely to receive statins, b-blockers, and ACE inhibitors than survivors of acute coronary syndromes, 20, 25 and our data suggest that enhanced use of these medications would improve long-term outcomes after nontransplant cardiac surgery, especially CABG. Thus even in patients without heart failure or a prior MI, strong consideration should be given to the prescription of b-blockers after CABG. All columns report frequencies (percentages) unless otherwise stated. Only 2 patients were taking angiotensin receptor blockers preoperatively, and thus angiotensin receptor blockers are not included in this table. SD, Standard deviation; CABG, coronary artery bypass grafting; MI, myocardial infarction; GI, gastrointestinal; ACE, angiotensin-converting enzyme. *Duke Jeopardy scores were only calculated for patients undergoing coronary artery bypass grafting. yCreatinine values were unavailable for 1305 patients. zNote that these mean crossclamp times exclude the 14 b-blocker users and 3 nonusers who had their coronary artery bypass grafting done off pump.
